Research,
FDA,
Clinical trials,
Biotechnology,
Health,
Pharmaceutical,
Other Science,
Science,
Oncology,
Monoclonal antibodies,
Medical specialties,
Cytokines,
Branches of biology,
Medicine,
Immunology,
Lenzilumab,
Granulocyte-macrophage colony-stimulating factor,
Cytokine,
Colony-stimulating factor,
Interleukins,
Namilumab Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.
Key Points:
- Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.
- All three positions report to Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen.
- He is also the founder of Black Horse Capital with decades of biotechnology investment experience.
- We are pleased that both Dr. Chappell and Mr. Tousley, who have previously operated in interim capacities with the Company, have joined us as full-time members of the Humanigen team, stated Dr. Cameron Durrant.
Biotechnology,
Health,
Pharmaceutical,
Clinical trials,
Oncology,
Branches of biology,
Medicine,
Clinical medicine,
Cancer treatments,
Gene therapy,
Cytokines,
Immune system,
Chimeric antigen receptor T cell,
Lymphoma,
Axicabtagene ciloleucel,
EMR1,
Macrophage colony-stimulating factor Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.
Key Points:
- Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.
- We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
- In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
- Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration.
Infectious diseases,
FDA,
Clinical trials,
Stem cells,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Oncology,
Branches of biology,
Medical specialties,
Intensive care medicine,
Cytokines,
Respiratory diseases,
Medical emergencies,
Immune system,
Acute respiratory distress syndrome,
Respiratory distress syndrome,
Macrophage colony-stimulating factor,
Monocyte,
Granulocyte-macrophage colony-stimulating factor Nevertheless, this secondary analysis was conducted to provide context for the data generated to date with lenzilumab.
Key Points:
- Nevertheless, this secondary analysis was conducted to provide context for the data generated to date with lenzilumab.
- ET to discuss the results of the initial cohort of patients treated with lenzilumab.
- Patients with severe cases of COVID-19 experience severe viral pneumonia that can progress to acute respiratory distress syndrome (ARDS), respiratory failure and death.
- In severe and critical patients with COVID-19, published research suggests GM-CSF as the key link between pathogenic Th1 cells and inflammatory monocytes, which secrete additional GM-CSF4.
Biotechnology,
Infectious diseases,
Health,
Pharmaceutical,
Clinical trials,
Medical specialties,
Medicine,
Immunology,
Infectious diseases,
Cytokines,
Inflammatory cytokine,
Pneumonia,
Cytokine Key Points:
- The manuscript, titled First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia was published online at medRxiv.org ( www.medrxiv.org/content/10.1101/2020.06.08.20125369v1 ).
- Patients showed rapid clinical improvement with a median time to recovery of five days, median time to discharge of five days and 100% survival to the data cut-off date.
- Patients also demonstrated rapid improvement in oxygenation, temperature, inflammatory cytokines and key hematological parameters consistent with improved clinical outcomes.
- All patients were hospitalized in the Mayo Clinic system and had severe or critical pneumonia as a result of COVID-19.
We look forward to this clinical collaboration with Humanigen and to evaluating the combination of lenzilumab and Yescarta in our clinical trial.
Key Points:
- We look forward to this clinical collaboration with Humanigen and to evaluating the combination of lenzilumab and Yescarta in our clinical trial.
- Humanigen has pioneered the approach to neutralizing GM-CSF to improve CAR T, said Cameron Durrant, MD, Chief Executive Officer, Humanigen.
- Lenzilumab, alone or in combination with other therapies such as Yescarta, is investigational and has not been approved by the FDA or any regulatory authority for any uses.
- Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving Yescarta, including concurrently with CRS or after CRS resolution.
DALLAS, May 22, 2018 /PRNewswire/ --Lupagen, Inc. ( www.lupagen.com ), a medical device company developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy products, today announced the intent to explore the development of a bedside, point-of-care delivered CAR-T therapy with Humanigen, Inc. (OTCQB: HGEN), a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology treatments.
Key Points:
- DALLAS, May 22, 2018 /PRNewswire/ --Lupagen, Inc. ( www.lupagen.com ), a medical device company developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy products, today announced the intent to explore the development of a bedside, point-of-care delivered CAR-T therapy with Humanigen, Inc. (OTCQB: HGEN), a biopharmaceutical company developing cutting-edge CAR-T optimization and oncology treatments.
- Lupagen and Humanigen are planning work to investigate the potential of a bedside CAR-T therapy created from Humanigen's Ifabotuzumab, a first-in-class, monoclonal antibody targeting the EphA3 receptor tyrosine kinase.
- "A bedside, closed-loop, point-of-carepatient-connected systemallows patient cells to be harvested, reprogrammed or modified, then reinfused at the bedside.
- Lupagen, Inc. is a privately held early stage medical device company developing first-in-class cell and gene therapy delivery technologies for next generation CAR-T, gene editing and immunotherapy products based on their patent-pending bedside, closed-loop, point-of-care technology.
